美國體外診斷臨床化學和免疫分析市場（2020年）-促進大量測試需求的增長

由於新的冠狀病毒感染（COVID-19）感染的傳播，美國的體外診斷市場得到了進一步發展。許多臨床實驗室和製藥商都在競爭開髮冠狀病毒（SARS-Cov-2）的檢測方法，以滿足不斷增長的檢測需求。它還有望與物聯網（IoT），雲計算，大數據等相關聯。另一方面，由於不確定性的嚴重性，併購（合併/收購）和商業聯盟一直表現不佳。

本報告分析了美國體外診斷（IV）的臨床化學和免疫測定（immunoassay）市場，並分析了市場的基本結構，主要的推動者和抑制者，以及最近的主要市場和產品。我們將為您提供有關趨勢（資本交易等），市場規模趨勢，未來增長機會以及需要解決的問題的信息。

目錄

戰略挑戰

• 為什麼增長更加困難？
• 關於戰略要務8？
• 三大戰略挑戰：對體外診斷臨床化學/免疫分析市場的影響
• 通過增長機會促進戰略要務8？

增長機會分析

• 生長促進劑
• 生長抑製劑
• 併購（合併/收購），合夥活動
• 選擇與產品相關的活動

增長機會

• 生長機會（1）：血清學檢查診斷COVID-19
• 生長機會（2）：阿爾茨海默氏病診斷的生物標誌物
• 增長機會（3）：用於優化流程的物聯網
• 增長機會（4）：直銷檢驗服務

Serology Assays for COVID-19 Diagnosis Present an Immediate Growth Opportunity

The Transformational Health team at Frost & Sullivan provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry.

The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recent COVID-19 pandemic. Clinical laboratories and manufacturers have been vying to develop SARS-Cov-2 assays to serve the rising demand for testing. In these uncertain times, mergers, acquisitions, and partnerships have seen a considerable dip as compared with the previous year.

The US government and healthcare agencies are supporting telehealth and innovative and clinically vetted direct-to-consumer diagnostic testing services. Partnerships with digital vendors and automation companies are expected to empower core diagnostic companies with Internet of Things (IoT), cloud, and Big Data capabilities. Given these trends, it is important to understand the market dynamics to remain competitive and successful in the in vitro diagnostics market.

This report offers insightful analysis in the form of key growth opportunities that center on the use of serological testing, unmet testing needs for neurodegenerative disorders, process flow improvement through IoT technologies, and the opportunity to include direct-to-consumer capabilities in business models.

Research Highlights:

• Market drivers and restraints

• Recent product trends and business updates from the US market

• Growth opportunities

• Strategic imperatives

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top Three Strategic Imperatives on the US In Vitro Diagnostics Clinical Chemistry and Immunoassay Market
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Growth Drivers
• Growth Restraints
• Merger, Acquisition, and Partnership Activities
• Select Product-related Activities
• Select Product-related Activities (continued)

Growth Opportunity Universe

• Growth Opportunity 1: Serology Assays for COVID-19 Diagnosis
• Growth Opportunity 1: Serology Assays for COVID-19 Diagnosis (continued)
• Growth Opportunity 2: Biomarkers for Alzheimer's Disease Diagnosis
• Growth Opportunity 2: Biomarkers for Alzheimer's Disease Diagnosis (continued)
• Growth Opportunity 3: IoT for Optimizing Process Flow
• Growth Opportunity 3: IoT for Optimizing Process Flow (continued)
• Growth Opportunity 4: Direct-to-Consumer Testing Services
• Growth Opportunity 4: Direct-to-Consumer Testing Services (continued)
• List of Exhibits
• Legal Disclaimer